Takeda Files DPP-4 Inhibitor NDA, Poised To Best Bristol/AstraZeneca, Novartis In Race For Second To Market

NDA for alogliptin submitted Dec. 27, Takeda tells “The Pink Sheet” DAILY, giving the drug an expected Oct. 27, 2008, PDUFA date with standard review.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet